ArticleHuman vaccines & immunotherapeutics2020
Vaccine strategies to induce broadly protective immunity to rhinoviruses.
Article in Human vaccines & immunotherapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Induction of neutralising antibodies against conserved rhinovirus capsid protein VP4 is dependent on presentation of VP4 peptide immunogens in a virus-like conformation.PLoS pathogens · 2026Article
- Expression analysis of the IL-23/Th17 pathway in children with rhinovirus infection.Italian journal of pediatrics · 2025Article
- DMSO might impact ligand binding, capsid stability, and RNA interaction in viral preparations.Scientific reports · 2024Article
- Characteristics of upper respiratory tract rhinovirus in children with allergic rhinitis and its role in disease severity.Microbiology spectrum · 2024Article
- Immune interface interference vaccines: An evolution-informed approach to anti-bacterial vaccine design.Microbial biotechnology · 2024Article
- RVdb: a comprehensive resource and analysis platform for rhinovirus research.Nucleic acids research · 2024Article
- Article
- Respiratory Viral and Bacterial Exacerbations of COPD-The Role of the Airway Epithelium.Cells · 2022Review
- Human Rhinoviruses in Adult Patients in a Tertiary Care Hospital in Germany: Molecular Epidemiology and Clinical Significance.Viruses · 2021Article
- Review
- Mechanisms of Rhinovirus Neutralisation by Antibodies.Viruses · 2021Review
- Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks.Journal of clinical medicine · 2020Article
- A cross-reactive mouse monoclonal antibody against rhinovirus mediates phagocytosis in vitro.Scientific reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rhinoviruses are ubiquitous human pathogens of the upper respiratory tract and are the major cause of acute exacerbations of asthma and chronic obstructive pulmonary disease. At least 160 antigenically distinct serotypes or strains have been identified and protective immunity is largely serotype specific. Attempts to produce vaccines that induce broad immunity have met with limited success which is due in part to this antigenic diversity and a lack of information regarding the ideal protective immune responses. Recent approaches identifying conserved rhinovirus epitopes and better definitions of the immune correlates of protection have raised hope. Here, these newer findings are outlined and the prospects for such a universal rhinovirus vaccine are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.